ArticleAmerican journal of physiology. Endocrinology and metabolism2019
Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota.
Article in American journal of physiology. Endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials.Nutrients · 2020Pooled it
- Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.Frontiers in endocrinology · 2020Pooled it
- Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Trial
- Metformin and Myo-Inositol: A Comparative Analysis.Gynecologic and obstetric investigation · 2026Review
- Mediating role of aging and obesity in the relationship between dietary index for gut microbiota and metabolic syndrome and its potential regulatory mechanisms.European journal of medical research · 2025Article
- Metformin effects on respiratory and metabolic outcomes in asthma and metabolic syndrome: a double-blind, randomized, placebo-controlled clinical trial.Annals of medicine and surgery (2012) · 2025Article
- Metabolic syndrome and dermatological diseases: association and treatment.Nutrition & metabolism · 2025Review
- Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan.Journal of diabetes research · 2025Article
- Specific Alternation of Gut Microbiota and the Role ofJournal of microbiology and biotechnology · 2024Article
- Bile salt signaling and bile salt-based therapies in cardiometabolic disease.Clinical science (London, England : 1979) · 2024Article
- Anti‑inflammatory effect of metformin against an experimental model of LPS‑induced cytokine storm.Experimental and therapeutic medicine · 2023Article
- Article
- Metformin: update on mechanisms of action and repurposing potential.Nature reviews. Endocrinology · 2023Review
- Detection and Quantification of Some Ethanol-Producing Bacterial Strains in the Gut of Mouse Model of Non-Alcoholic Fatty Liver Disease: Role of Metformin.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity.Pulmonary therapy · 2023Review
- Dietary Supplementation of Cedryl Acetate Ameliorates Adiposity and Improves Glucose Homeostasis in High-Fat Diet-Fed Mice.Nutrients · 2023Article
- Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target.International journal of molecular sciences · 2023Article
- Insulin Resistance and Acne: The Role of Metformin as Alternative Therapy in Men.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome.International journal of molecular sciences · 2022Article
- Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders. Several mechanisms of action for metformin have been proposed, including that it acts as an anti-inflammatory agent, possibly as a result of its impact on intestinal microbiota. In accord with this possibility, we observed herein that, in mice with diet-induced metabolic syndrome, metformin impacts the gut microbiota by preventing its encroachment upon the host, a feature of metabolic syndrome in mice and humans. However, the ability of metformin to beneficially impact metabolic syndrome in mice was not markedly altered by reduction or elimination of gut microbiota, achieved by the use of antibiotics or germfree mice. Although reducing or eliminating microbiota by itself suppressed diet-induced dysglycemia, other features of metabolic syndrome including obesity, hepatic steatosis, and low-grade inflammation remained suppressed by metformin in the presence or absence of gut microbiota. These results support a role for anti-inflammatory activity of metformin, irrespective of gut microbiota, in driving some of the beneficial impacts of this drug on metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.